Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.05 +1.2%	$2.23	$0.80 ▼ $3.14	$799.73M	0.88	3.84 million shs	2.14 million shs
CRGX CARGO Therapeutics	$4.22 0.0%	$4.22	$3.00 ▼ $25.45	$194.82M	0.47	543,773 shs	80,848 shs
NRIX Nurix Therapeutics	$10.47 -1.6%	$10.39	$8.18 ▼ $29.56	$801.24M	2.23	872,107 shs	192,384 shs
XERS Xeris Biopharma	$4.95 -1.9%	$4.67	$1.96 ▼ $6.07	$774.89M	1.1	1.96 million shs	646,962 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+4.51%	+6.36%	+23.87%	+62.70%	+192.23%
CRGX CARGO Therapeutics	+2.18%	+2.93%	-7.05%	+12.23%	-76.61%
NRIX Nurix Therapeutics	+5.98%	+6.51%	-6.99%	-31.13%	-29.58%
XERS Xeris Biopharma	+5.44%	+3.28%	+14.29%	+31.59%	+161.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.1308 of 5 stars	4.6	1.0	4.0	3.2	0.0	0.6
CRGX CARGO Therapeutics	2.3107 of 5 stars	2.9	0.0	0.0	3.3	1.7	1.3
NRIX Nurix Therapeutics	1.8729 of 5 stars	4.4	0.0	0.0	2.4	0.8	0.0
XERS Xeris Biopharma	3.7828 of 5 stars	3.4	1.0	4.2	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.63	117.57% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	255.62% Upside
NRIX Nurix Therapeutics	2.84	Moderate Buy	$30.44	190.78% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	26.39% Upside

Current Analyst Ratings Breakdown

Latest CRGX, XERS, AKBA, and NRIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/9/2025	NRIX Nurix Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $25.00
4/9/2025	NRIX Nurix Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $35.00
4/9/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/2/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/1/2025	AKBA Akebia Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
3/17/2025	NRIX Nurix Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$184.91M	4.32	N/A	N/A	($0.16) per share	-19.03
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$9.84 per share	N/A
NRIX Nurix Therapeutics	$56.42M	14.15	N/A	N/A	$7.44 per share	1.41
XERS Xeris Biopharma	$222.55M	3.47	N/A	N/A	($0.05) per share	-98.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$51.92M	-$0.21	N/A	N/A	N/A	-27.07%	N/A	-20.57%	8/14/2025 (Estimated)
CRGX CARGO Therapeutics	-$98.15M	-$4.62	N/A	N/A	N/A	N/A	-38.16%	-33.94%	8/11/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-354.85%	-53.65%	-38.59%	7/10/2025 (Estimated)
XERS Xeris Biopharma	-$62.26M	-$0.30	N/A	N/A	N/A	-33.69%	N/A	-17.38%	8/14/2025 (Estimated)

Latest CRGX, XERS, AKBA, and NRIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million
3/13/2025	Q4 2024	AKBA Akebia Therapeutics	-$0.05	-$0.10	-$0.05	-$0.10	$37.36 million	$46.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	N/A	1.52	1.21
CRGX CARGO Therapeutics	N/A	18.94	18.95
NRIX Nurix Therapeutics	N/A	6.46	6.46
XERS Xeris Biopharma	N/A	1.79	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
CRGX CARGO Therapeutics	93.16%
NRIX Nurix Therapeutics	N/A
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
CRGX CARGO Therapeutics	2.92%
NRIX Nurix Therapeutics	7.40%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	209.24 million	Optionable
CRGX CARGO Therapeutics	116	46.11 million	45.39 million	N/A
NRIX Nurix Therapeutics	300	76.24 million	70.42 million	Optionable
XERS Xeris Biopharma	290	156.39 million	142.28 million	Optionable

CRGX, XERS, AKBA, and NRIX Headlines

Recent News About These Companies

Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 29 at 3:38 AM | marketbeat.com

BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 28 at 3:16 AM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street Zen

May 24, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Downgraded to "Hold" Rating by Wall Street Zen

May 23, 2025 | americanbankingnews.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Stonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 20, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.

May 20, 2025 | marketbeat.com

Leerink Partnrs Weighs in on Xeris Biopharma Q2 Earnings

May 17, 2025 | marketbeat.com

Parkman Healthcare Partners LLC Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 16, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Lowers Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 13, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Driehaus Capital Management LLC Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 12, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Tudor Investment Corp ET AL Reduces Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 9, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025 | businesswire.com

4XERS : Earnings Outlook For Xeris Biopharma Holdings

May 7, 2025 | benzinga.com

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025 | seekingalpha.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Reduced by Caxton Corp

May 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRGX, XERS, AKBA, and NRIX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.04 +0.04 (+1.16%)

As of 12:13 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CARGO Therapeutics NASDAQ:CRGX

$4.22 0.00 (-0.05%)

As of 12:13 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Nurix Therapeutics NASDAQ:NRIX

$10.47 -0.17 (-1.60%)

As of 12:12 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Xeris Biopharma NASDAQ:XERS

$4.94 -0.10 (-1.88%)

As of 12:12 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time